Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt (2016 - 2023)

Historic Total Debt for Cartesian Therapeutics (RNAC) over the last 9 years, with Q4 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Total Debt rose 778.69% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 778.69%. This contributed to the annual value of $28.3 million for FY2023, which is 778.69% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Total Debt stood at $28.3 million for Q4 2023, which was up 778.69% from $24.0 million recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Total Debt ranged from a high of $28.3 million in Q4 2023 and a low of $14.8 million during Q2 2020
  • For the 5-year period, Cartesian Therapeutics' Total Debt averaged around $23.6 million, with its median value being $25.0 million (2021).
  • Per our database at Business Quant, Cartesian Therapeutics' Total Debt plummeted by 3116.3% in 2020 and then soared by 7003.98% in 2021.
  • Over the past 5 years, Cartesian Therapeutics' Total Debt (Quarter) stood at $18.9 million in 2019, then surged by 31.15% to $24.8 million in 2020, then increased by 3.39% to $25.6 million in 2021, then increased by 2.45% to $26.3 million in 2022, then increased by 7.79% to $28.3 million in 2023.
  • Its Total Debt was $28.3 million in Q4 2023, compared to $24.0 million in Q2 2023 and $26.4 million in Q1 2023.